Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026

Methicillin-resistant Staphylococcus aureus (MRSA) is a widespread Gram-positive bacterium spread through direct contact with infected individuals. It is characterized by multiple drug resistance to beta-lactam antibiotics, including methicillin, penicillin, and oxacillin.

This report provides an assessment of the pipeline, clinical, and commercial landscape of MRSA. Overall, GlobalData expects new drug approvals and key patent expiries to drive MRSA market growth over the next decade (2016–2026).

Scope

GlobalData’s Methicillin-resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global MRSA market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MRSA market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Allergan

Merck & Co.

The Medicines Company

Sanofi

Pfizer

Theravance Biopharma

Kyorin Pharmaceuticals

Melinta Therapeutics

Atox Bio Ltd

Paratek Pharmaceuticals

Bayer AG

Nabriva Therapeutics

Motif BioSciences

Melinta Therapeutics

MicuRx Pharmaceuticals

Citius Pharmaceuticals

TaiGen Biotechnology

Basilea Pharmaceuticals

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Definition & Epidemiology Overview

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in MRSA

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.3 Japan & China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports